Navigation Links
Skin Rash Actually Signifies Better Outcomes for Pancreatic and,Lung Cancer Patients

nt because of the rash, yet those are the ones who are most likely to benefit,” Wacker said. “This is a critical problem and rather than permanently discontinue treatment, patients should talk to their doctor about an effective and proactive strategy to manage the rash while continuing Tarceva therapy.”

According to the researchers, these rashes can be controlled with mild steroids or antibiotics, and in most cases, they will improve with treatment. They are believed to be due to an inflammatory response as a result of EGFR inhibition in skin tissue, Wacker said.

The analysis looked at two placebo-controlled, double-blind, randomized, Phase III clinical trials testing Tarceva in advanced non-small cell lung cancer and pancreatic cancer ? studies which led to approval of the agent for treating both cancers. Wacker and his team excluded patients who died in the first month after starting the study because they may not have had time to develop the rash or the rash may have been under-reported in these ill patients.

Of the 673 patients in the lung cancer study, called BR.21, and in the Tarceva-treated group, 81 percent developed a rash, the majority of which was grade 2 (The study graded rashes from 1, relatively mild, to 4, severe). The researchers found that the presence of any rash correlated with overall and progression-free survival and that these correlations increased with the grade of rash. Specifically, Tarceva-treated patients who did not develop a rash survived a median of 3.3 months, compared to 7.1 months for those with a grade 1 rash, and 11.1 months for patients with more severe, grade 2 rashes.

They also found, however, that 18 percent of patients treated with a placebo also developed a rash, and that overall survival in these patients was also significantly longer (a median of 8.2 months compared to 4.7 months), compared to placebo patients who didn’t develop a rash. “We d
'"/>




Page: 1 2 3 4

Related medicine technology :

1. New Advances in Gastric Diagnostics: Smaller is Better
2. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
3. Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease
4. The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem Cells Work Better
5. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
6. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
7. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
8. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
9. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
10. Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
11. Clinical Trial Results Change Standard of Care for Pancreatic Cancer Patients, Future Therapies Discussed
Post Your Comments:
(Date:8/28/2014)...  Seres Health, a clinical-stage therapeutics company developing ... microbiome, announced today that Dr. David Cook ... Chief Scientific Officer, will be presenting at the ... (ICAAC). The presentation will highlight the scientific and ... bacterial spores derived from the human microbiome, and ...
(Date:8/28/2014)... PITTSBURGH , Aug. 28, 2014 /PRNewswire-iReach/ -- ... exhibiting at the 9 th Annual Global ... , September 8-9 th . The Global ... industry leaders in small molecule and biologic pharmaceutical ... address challenges that today,s manufacturers face, such as ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com ... report is available in its catalogue: ... Asia-Pacific Markets to 2020 - Novel ... in Newly Diagnosed and Recurrent GBM ... Glioblastoma Multiforme Therapeutics ...
Breaking Medicine Technology:Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... WILMINGTON, Del., Oct. 26 Next Intelligence Corporation ( ... today announced the expansion of its channel program for ... and system integrators (SI) to explore the growing health ... members sales leads, education on technical and selling aspects ...
... (Nasdaq: GTIV ), the nation,s largest provider of ... present at the Oppenheimer 21st Annual Healthcare Conference in New ... and the Credit Suisse 2010 Healthcare Conference in Phoenix, AZ ... 10, 2010. The presentations will be available to ...
Cached Medicine Technology:Next Intelligence Health Expands US Channel Program 2Gentiva® Health Services to Present at the Oppenheimer and Credit Suisse Healthcare Conferences 2Gentiva® Health Services to Present at the Oppenheimer and Credit Suisse Healthcare Conferences 3
(Date:8/29/2014)... Aug. 29, 2014 (HealthDay News) -- The main ... the Middle East and North Africa originated in ... studied so-called community-acquired methicillin-resistant Staphylococcus aureus ... have not recently been hospitalized. These infections typically ... person-to-person contact or through touching contaminated objects such ...
(Date:8/29/2014)... August 29, 2014 For the fifth ... (Meso Foundation) will be observing September 26th as Mesothelioma ... Plaza, in New York. , Members of the ... RSVP . The Foundation will be providing t-shirts and ... years, mesothelioma community members have received attention from ...
(Date:8/29/2014)... 29, 2014 PreDiabetes Centers , the ... season by offering Web shoppers a 20% discount off orders ... the Company’s online healthy living shop, beginning September 1. ... priority when heading into the chilly fall season. , Autumn’s ... this season, people usually ditch the healthy salads and opt ...
(Date:8/29/2014)... August 29, 2014 Innovations Television, produced by ... upcoming episodes of Innovations, focusing on health and elderly care, ... show the number of Americans over 65 will nearly double ... to 20% in 2030, for a total of 72 million ... health, most have at least one chronic condition and use ...
(Date:8/29/2014)... Raleigh, NC (PRWEB) August 29, 2014 ... validated the idea that progression-free survival correlates with overall ... article on the new research. Click here to ... UK and The Netherlands studied the cases of 523 ... European chemotherapy studies. , “PFSR-18 [progression-free survival at ...
Breaking Medicine News(10 mins):Health News: European MRSA Originated in Sub-Saharan Africa, Study Finds 2Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2Health News:PreDiabetes Centers Online Store Launches Fall Savings Event 2Health News:Innovations with Ed Begley, Jr., Seeking Content for Upcoming Series on Health and Elder Care 2Health News:European Study Says Disease Progression Predicts Mesothelioma Survival Better Than Treatment Response, According to Surviving Mesothelioma 2
... Heart Failure Nurses in Boston, June ... 26-28, ... (AAHFN) 2008 Annual Meeting "Raising the Bar in Heart,Failure Care" is scheduled ... research and ways to,improve patient care. The compelling agenda and wonderful ...
... VYTEX(TM) NRL: THE NEW STANDARDIZED SOURCE MATERIAL FOR THE ... PRODUCTS ... Rapra Technology Limited has invited,Vystar Corporation to present its ... Dispersions Conference 2008 in Madrid in,January. "Vytex(TM) Natural ...
... patients with advanced kidney cancer whose options run out after ... , The study, presented today (Wednesday) at the European ... drug, axitinib, shrank tumours and delayed progression of the disease ... to treat. , In the study, scientists gave axitinib to ...
... Paramount Acquisition,Corp. (OTC Bulletin Board: PMQC, PMQCU, PMQCW) ... directors has established the close of,business on October 1, ... will be entitled to receive notice of and to ... held to consider and vote,on the previously announced acquisition ...
... Consider Proposals and Variations, LOS ANGELES, ... ISCR) a leading e-health Wi-Fi PDA technology ... DME and EMR applications,and the distributor of ... surgical products, announced today that its Board ...
... Spain: Using an ultrasound-guided fine needle to biopsy lymph ... worldwide from having to undergo unnecessary and sometimes unpleasant ... research indicates. , In a study presented today ... Barcelona, scientists found that the less invasive technique produced ...
Cached Medicine News:Health News:AAHFN's 2008 Annual Meeting in Boston Will Be 'Raising the Bar in Heart Failure Care' 2Health News:Global Latex Conference to Showcase Vytex(TM) NRL 2Health News:Experimental drug shows promise in advanced kidney cancer 2Health News:Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx 2Health News:Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx 3Health News:Paramount Acquisition Corp. Announces Record Date of October 1, 2007 for Proposed Acquisition of Chem Rx 4Health News:InstaCare Corp. Reviewing M&A Plans 2Health News:Less invasive lymph node biopsy method could spare thousands unnecessary operations 2
Cuffed pediatric endotracheal tubes, available from 2.5 mm to 4.5 mm inside diameter. Ruschelit® PVC. Magill tip - nasoral. X-ray opaque line. Graduated. Single use. Sterile...
Ruschelit® PVC. Murphy eye-nasoral. Black positioning ring. High volume/low pressure cuff. X-ray opaque line. Graduated. Single use....
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
... eye. Laser resistant foam surrounds the lower 17cm ... other) 40cm (16") long, Single Use. The tracheal ... optimum visibility within the operating site, while maintaining ... laser-guard of approx. 17cm in length proximal to ...
Medicine Products: